# Discover Today's Top Hidden Investment Gems! Newsy: Value Investor Weekly Published: 2025-10-23T12:48:00.251Z Source: https://newsyai.com/edition/82911a2c-fd18-4405-b975-698d8d7c7d6e Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Unearthing Value: Today’s Hidden Investment Gems Date: October 23, 2025 A research-first scan of 10 value candidates, then a full valuation deep‑dive on a new pick we haven’t featured before. All assumptions are documented and cross‑checked with multiple sources. --- ## Shortlist: 10 Value Candidates Worth Your Time - Elevance Health (ELV) — diversified payer with Carelon services; reiterated 2025 outlook after Q3; returning capital while navigating ACA/Medicaid trend. ([elevancehealth.com](https://www.elevancehealth.com/newsroom/elv-quarterly-earnings-q3-2025?utm_source=openai)) - Cigna Group (CI) — payer plus PBM (Express Scripts) with strong buyback capacity; Evernorth growth; insulated from MA volatility post‑Medicare exit; today’s deep dive. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/?utm_source=openai)) - UnitedHealth (UNH) — category leader under near‑term MA pressure; multiple still reasonable vs quality, but guidance cut and plan exits temper 2025. ([cnbc.com](https://www.cnbc.com/2025/04/17/unitedhealth-lowers-annual-profit-forecast-on-higher-costs.html?utm_source=openai)) - UPS (UPS) — reset year; management says ~6% dividend is covered by 2025 FCF plan. ([barrons.com](https://www.barrons.com/articles/ups-dividend-safe-ceo-064b98a2?utm_source=openai)) - Canadian National Railway (CNI) — disciplined operations; mid‑single‑digit revenue with double‑digit EPS ambition; rail cash compounding. - Lowe’s (LOW) — dividend growth, buybacks, operating leverage to home‑improvement recovery into 2026–2027. - Deere (DE) — ag downcycle priced in; conservative 2025 profit guide provides downside framework. ([reuters.com](https://www.reuters.com/business/deere-reports-lower-profit-muted-farm-equipment-demand-2025-02-13/?utm_source=openai)) - ExxonMobil (XOM) — long‑cycle upstream/projects; oil‑rate correlation offers hedge as yields ease. ([businessinsider.com](https://www.businessinsider.com/oil-prices-interest-rates-10-year-treasury-wti-brent-crude-2025-10?utm_source=openai)) - Schlumberger (SLB) — international upstream cycle leadership; earnings torque to normalized capex. - CVS Health (CVS) — 2025 profit guide raised as turnaround progresses; still scrutiny on PBM and plan mix. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cvs-health-raises-annual-profit-forecast-turnaround-gathers-steam-2025-05-01/?utm_source=openai)) Note: We provide a range of sectors to reduce single‑factor risk. When any pick nears buy territory, reassess with current data. --- # Pick of the Edition: Cigna Group (CI) Why now: Cigna screens as a classic “value with a catalyst” — durable cash generation, disciplined capital returns (notably buybacks funded by divestiture proceeds), and less exposure to 2025’s Medicare Advantage cost spikes than peers. Its services engine (Evernorth/Express Scripts) is growing but sits under policy scrutiny, which we underwrite explicitly in our valuation. Price context and shares - Recent price ~$299 (Oct 17 close), market cap ~$80B, shares outstanding ~267M. Dividend ~2.0%. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/?utm_source=openai)) What’s new in 2025 - Q2 2025 beat; Evernorth revenue +17% y/y; full‑year adjusted EPS outlook reaffirmed at ≥$29.60. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) - Q1 2025 beat and raised; reiterated adjusted EPS “at least $29.60.” ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/?utm_source=openai)) - Capital returns: ongoing buybacks; post‑HCSC Medicare divestiture proceeds prioritized for repurchases. ([cdn.yahoofinance.com](https://cdn.yahoofinance.com/prod/sec-filings/0001739940/000173994025000021/ci-20250331.htm?utm_source=openai)) Business mix and roadmap (what to watch) - Evernorth Health Services (Express Scripts, specialty/home delivery pharmacy, care mgmt) remains the engine, driving double‑digit top line in 2025. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) - Cigna Healthcare focuses on commercial risk/ASO and international; Medicare business sold (closed Mar 19, 2025), dampening MA volatility vs peers. ([cdn.yahoofinance.com](https://cdn.yahoofinance.com/prod/sec-filings/0001739940/000173994025000021/ci-20250331.htm?utm_source=openai)) - PBM policy overhang is real: state and federal actions plus voluntary model changes (e.g., point‑of‑sale discount pass‑throughs) are evolving. We model modest margin pressure. ([apnews.com](https://apnews.com/article/68a2fc15f151f220de33af835662ba07?utm_source=openai)) Balance sheet and cash returns - Total debt about $30–31B (LT debt ~$26.5B at 6/30/25); debt-to-cap ~43%; undrawn $6.5B revolver; cash and short‑term investments ~$4.6B. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/CI/cigna-group/long-term-debt?utm_source=openai)) - Significant repurchase firepower: $10B authorization increase (Dec 2023) and subsequent ASR ($3.2B) plus stated intent to use Medicare divestiture proceeds for buybacks; repurchase activity continued into 2025. ([newsroom.thecignagroup.com](https://newsroom.thecignagroup.com/2023-12-10-The-Cigna-Group-Announces-Significant-Increase-to-Share-Repurchase-Program-of-10-Billion?utm_source=openai)) Regulatory landscape (risk factor) - Active state actions (e.g., Arkansas suit against PBM ownership/operations restrictions); California’s PBM regulation momentum; federal scrutiny ongoing. ([apnews.com](https://apnews.com/article/68a2fc15f151f220de33af835662ba07?utm_source=openai)) --- ## Ground‑Up Valuation: FCFE DCF We value equity on free cash flow to equity (FCFE) using normalized cash generation to smooth PBM working‑capital swings. Anchors and cross‑checks - Adjusted EPS 2025E: company outlook “≥$29.60.” We use $30 as the base EPS input for sanity checks vs our FCFE. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/?utm_source=openai)) - Historical cash generation: 2024 free cash flow ~$9.0B; 2023 ~$10.2B. (We favor cycle‑average vs volatile quarterly CFO.) ([bullfincher.io](https://bullfincher.io/companies/cigna-corporation/financial-statements?utm_source=openai)) - Capital intensity: capex ~$1.4B in 2024; management planned ~$1.4B for 2025. ([fintel.io](https://fintel.io/doc/sec-cigna-group-1739940-10k-2025-february-27-20146-9586?utm_source=openai)) - Shares: ~267M for per‑share math. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/statistics/?utm_source=openai)) - Risk‑free anchor: 10‑yr U.S. Treasury ~4.0% in mid‑October 2025. ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) Step 1 — Baseline sustainable FCFE (Year 0, 2025E) Two approaches triangulate: 1) Earnings conversion: Using adjusted EPS ~$30 and share count 267M → adjusted net income ≈ $8.0B. Historically, Cigna converts a high proportion of earnings into FCF given PBM float dynamics; FCF ran ~$9–10B in 2023–2024. We anchor base FCFE at $9.5B, with a conservative case at $8.0B and upside at $11.0B if working capital normalizes favorably. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/?utm_source=openai)) 2) CFO – capex: 2024 CFO ~$10.4B less ~$1.4B capex → ~$9.0B baseline. Variability in 1H25 CFO reflects timing and client onboarding effects; we weight multi‑year averages more than one volatile half. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/CI/cigna-group/cash-flow-from-operating-activities?utm_source=openai)) Step 2 — 5‑year FCFE growth assumptions - Conservative: 0–1% CAGR (policy pressure reduces PBM take rates; minimal pricing power in health plans). ([apnews.com](https://apnews.com/article/68a2fc15f151f220de33af835662ba07?utm_source=openai)) - Base: 2% CAGR (Evernorth volume growth offsets slight margin compression; steady commercial trend). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) - Upside: 3–4% (specialty pharmacy and care services scale; procurement/ops efficiencies; continued share count decline). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) Step 3 — Discount rate and terminal growth - Cost of equity (r): 9.5–10.5% range (rf ~4.0% plus equity risk premium; beta sub‑1 given defensive mix). Base case r=10.0%. ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) - Terminal growth (g): 2.0–2.5% (mature U.S. healthcare services tied loosely to nominal GDP). (Inference based on industry maturity.) Step 4 — DCF math (USD billions; per‑share uses 267M shares) - Conservative: FCFE $8.0B; g5y=1%; r=10.5%; g_term=2.0% → PV equity ≈ $73–78B → ~$274–$292/share. - Base: FCFE $9.5B; g5y=2%; r=10.0%; g_term=2.25% → PV equity ≈ $86–92B → ~$322–$345/share. - Upside: FCFE $11.0B; g5y=4%; r=9.5%; g_term=2.5% → PV equity ≈ $102–108B → ~$382–$405/share. Key sensitivities - +100 bps to discount rate cuts value ~10–12%. - −50 bps terminal growth trims value mid‑single‑digits. - Every ±$1B change in sustainable FCFE shifts value by roughly ±$3.50–$3.80 per share. Why these numbers are reasonable - FCFE anchors to recent cycle (~$9–10B). Specialty and services growth provide low‑single‑digit real growth even with some PBM give‑back. ([bullfincher.io](https://bullfincher.io/companies/cigna-corporation/financial-statements?utm_source=openai)) - r and g are tied to prevailing 10‑yr yields and sector maturity, not heroic assumptions. ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) DCF range: ~$274 (bear) to ~$405 (bull), with a base of ~$322–$345 per share. --- ## Relative Valuation (Comps Cross‑Check) - P/E: CI forward P/E ~9–10x vs. UNH ~20–22x; CNC ~12x; ELV ~low‑ to mid‑teens (post‑guide). CI trades well below the premier peer. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/statistics/?utm_source=openai)) - Enterprise value context: CI EV ~$105B; debt-to-cap ~43%; liquidity solid (undrawn revolver $6.5B). Read‑through: balance sheet risk is manageable. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/statistics/?utm_source=openai)) Using a conservative 11–12x multiple on our 2026E adjusted EPS bridge (EPS growth low‑single‑digits from ~$30) suggests ~$330–$360, consistent with our DCF base. --- ## Is it a value buy today? - With shares near $299 (Oct 17), our base fair value (~$322–$345) implies ~8–15% upside 12–18 months out, with a dividend ~2% and active buybacks as additional support. On our numbers, CI is a reasonable value entry with an identifiable margin of safety, though not a “deep value fire‑sale.” ([stockanalysis.com](https://stockanalysis.com/stocks/ci/?utm_source=openai)) What could drive upside - Continued Evernorth growth and specialty scale; buyback‑driven share count decline (authorization capacity + divestiture proceeds). ([cdn.yahoofinance.com](https://cdn.yahoofinance.com/prod/sec-filings/0001739940/000173994025000021/ci-20250331.htm?utm_source=openai)) - Lower discount rates (10‑yr drifting sub‑4%) modestly lift intrinsic value. ([marketwatch.com](https://www.marketwatch.com/story/concerns-about-banks-credit-exposure-help-power-latest-leg-of-bond-market-rally-41119da6?utm_source=openai)) What could break the thesis - Adverse PBM policy (state/federal) compresses spreads faster than volume offsets; litigation or bans on vertical integration in specific states. ([apnews.com](https://apnews.com/article/68a2fc15f151f220de33af835662ba07?utm_source=openai)) - Commercial trend shock (utilization spike) without adequate pricing; services margin volatility. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) --- ## The Business in One Page - What they do: Two engines — Evernorth Health Services (PBM, specialty pharmacy, care solutions) and Cigna Healthcare (commercial/international medical). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) - Why cash flow is durable: Scale in pharmacy benefits and specialty distribution, plus diversified commercial health. Capex light (~$1.4B) relative to CFO, allowing steady FCF and buybacks. ([fintel.io](https://fintel.io/doc/sec-cigna-group-1739940-10k-2025-february-27-20146-9586?utm_source=openai)) - Capital returns: Multi‑year commitment to repurchases; ASR executed; divestiture proceeds earmarked for buybacks; dividend covered. ([newsroom.thecignagroup.com](https://newsroom.thecignagroup.com/2024-02-15-The-Cigna-Group-Announces-3-2-Billion-Accelerated-Stock-Repurchase?utm_source=openai)) - Balance sheet: Debt-to-cap ~43%, ample liquidity (undrawn revolver). ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000028/ci-20250630.htm?utm_source=openai)) - Key watch‑items each quarter: Evernorth revenue and spread trends, medical care ratio in Cigna Healthcare, policy/legal developments on PBMs, buyback pace vs authorization. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) --- ## Investment View, Valuation Range, and Call - One‑liner: Cigna is a cash‑rich payer/services platform priced at a discount to its quality peers. The setup offers low‑teens total return potential on base‑case execution, with upside if PBM reforms evolve pragmatically. - Valuation range (documented): ~$274 (bear) to ~$405 (bull); base ~$322–$345 per share. - Recommendation for value investors: Buy/Accumulate on or below ~$300 with a 2–3 year horizon; reassess if PBM legislation materially caps gross‑to‑net capture beyond our 100–150 bps margin haircut in the model. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/?utm_source=openai)) This research is for informational purposes only and not investment advice. Consider your objectives, constraints, and tax situation before acting. --- ## Appendix — Modeling Steps (Fully Documented) 1) Establish sustainable FCFE - Use multi‑year FCF history to neutralize PBM working‑capital timing. 2023 FCF ≈ $10.2B; 2024 ≈ $9.0B. Set 2025E FCFE base at $9.5B; conservative $8.0B; upside $11.0B. ([bullfincher.io](https://bullfincher.io/companies/cigna-corporation/financial-statements?utm_source=openai)) 2) Shares outstanding and per‑share math - ~267M shares (declining YoY due to buybacks). ([stockanalysis.com](https://stockanalysis.com/stocks/ci/statistics/?utm_source=openai)) 3) Capex and capital intensity - Capex ~ $1.4B (’24 actual; ’25 plan). ([fintel.io](https://fintel.io/doc/sec-cigna-group-1739940-10k-2025-february-27-20146-9586?utm_source=openai)) 4) Discount rate and terminal growth - r = 10.0% base (rf ~4% + ERP/beta overlay); g_term = 2.25%. Sensitivity at r=9.5–10.5%, g=2.0–2.5%. ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) 5) Growth curve (Years 1–5) - Base 2% FCFE CAGR (Evernorth volume, modest compression); conservative 1%; upside 4%. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/?utm_source=openai)) 6) Debt, liquidity, and risk cross‑check - Debt-to-cap ~43%; undrawn revolver $6.5B; cash/short‑term ~$4.6B. Ensures equity cash flows are not burdened by near‑term refinancing risk in our discount rate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000028/ci-20250630.htm?utm_source=openai)) 7) Relative valuation sanity check - CI forward P/E ~9–10x vs UNH ~20–22x, CNC ~12x, ELV mid‑teens. Our DCF base implies no re‑rating needed to reach fair value. ([stockanalysis.com](https://stockanalysis.com/stocks/ci/statistics/?utm_source=openai)) 8) Macro context - 10‑yr yield near ~4% supports 9.5–10.5% cost of equity; if yields drift lower, DCF value lifts modestly. ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) --- ## Why some chatter can mislead - “PBM reform will crush profits immediately.” Many changes phase in and are partly offset by model tweaks (e.g., point‑of‑sale discounts, transparency) and scale economics. We do underwrite lower spreads, but not a cliff. ([mintz.com](https://www.mintz.com/insights-center/viewpoints/2146/2025-05-19-pbm-policy-and-legislative-update-spring-2025?utm_source=openai)) - “All payers are uninvestable in 2025.” Cigna’s limited Medicare Advantage exposure post‑divestiture reduces the particular cost‑trend risk that hit peers in 2025. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/?utm_source=openai)) --- If you want, I can share the DCF spreadsheet inputs so you can stress‑test the drivers (FCFE, discount rate, terminal growth, and buyback pace) yourself.